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Abstract
BACKGROUND: Novel coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-CoV2 as 
a century concern affecting public health.
AIM: This study aimed to find the clinical and demographic characteristics of the patients died following COVID-19 
development at Modarres Hospital, Tehran, Iran.
METHODS: In this descriptive-analytical cross-sectional study, 62 patients died following COVID-19 were studied in 
terms of age, gender, body mass index, comorbidity, symptoms, liver profile, lipid profile, hemoglobin, platelet, white 
blood cell, lymphocytes, neutrophils, C-reaction protein, polymerase chain reaction (PCR), creatine phosphokinase, 
creatinine, blood urea nitrogen (BUN), potassium, magnesium, and sodium.
RESULTS: The results showed that 71% of patients were male and 69.4% had positive PCR test indicating low 
sensitivity of the test; 90.3% of patients were above 60 years old; 56.5 of patients had lymphocytopenia; the mean 
age was 67.62 ± 15.07 years; with symptoms lasting 6.24 days. The mean serum creatinine and BUN were 3.18 g/
dl and 125.9 mg/dl, respectively, indicating renal involvement. All patients had pulmonary involvement accompanied 
by other organ involvements. Regarding symptoms, 72% of patients showed fever. Some affected patients had 
diarrhea, lethargy, and fatigue. A comparison of comorbidities by gender showed no significant differences.
CONCLUSION: According to our results, the majority of patients were overweight. In people who are more than 60 
years, multi-organ failure was notable. Fever, cough, and shortness of breath were dominant symptoms like other 
studies, but neurological complications following COVID-19 as meningoencephalitis is possible that can be used as 
a differential diagnosis. We did not found differences between male and female regarding comorbidity, symptoms, 
and mortality rate.
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Introduction
Novel coronavirus (CoV) disease (COVID-19) is 
caused by severe acute respiratory syndrome (SARS)-
CoV2 and is a causative agent of a potentially lethal disease 
resulting in widespread concern in the global public health. 
CoV is one of the largest pathogens that mainly target the 
human respiratory tract. Previous outbreaks of CoV have 
included SARS and Middle East respiratory syndrome, 
which have long been known to be very threatening to 
public health. In late December 2019, a number of patients 
were admitted to hospitals whose initial diagnosis was a 
side effect of an unknown cause. The affected cases were 
associated with a wholesale market for seafood and wet 
animals in Wuhan, Hubei Province, China [1], [2]. Indeed, 
COVID-19 is a novel zoonotic disease caused by a novel 
CoV that started from China and bat is the reservoir hosts 
of novel CoVs [3]. Epidemiological studies of primary 
cases of CoV pneumoniae-2019 showed that many 
cases were exposed to the seafood market in Wuhan, 
China [4]. The basic reproduction number of COVID-19 
was reported from 2.24 to 3.58 [5].
The first official COVID-19 case in Iran was 
announced on February 19, 2020. On March 16, 2020, 
4 weeks later, the daily situation report on COVID-19 
showed about 5000 confirmed cases [6]. According to 
the World Health Organization (WHO), total confirmed 
cases of COVID-19 in Iran are 93,657 cases and show 
a decline slope so that in the last report, 80 deaths 
occurred on 30 April 2020 [7].
A study by Wang et al. showed that from 
January 10 to 24, 2019, the number of people infected 
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with the novel coronavirus-2019 in China increased 
31.4 times. They estimated the mortality rate of 2.84% 
for COVID-19. They also found that the male-to-female 
mortality ratio was 3.25 to 1; the median age of death 
was 75 years; the median time from the first symptoms to 
death was 14 days, and the median time from the initial 
symptoms to death in people aged 70 years and older 
(11 days) was shorter than people under 70 years (20 
days) [8]. A study by Li et al. revealed that the mean age 
of 425 patients infected with novel CoV was 59 years, 
of which 56% were men; the mean incubation period 
was 5.2 days, and almost half of the adult patients were 
60 years and older. The incubation period for COVID-
19 was 14 days after exposure, in which lots of cases 
occur approximately 4–5 days after exposure [9].
Detection of COVID-19 in most cases is not easy 
because most patients have mild or moderate syndrome 
with a strong prognosis. However, it may be necessary 
to identify an etiological factor in epidemiological studies, 
especially during epidemic outbreaks. Since the new 
CoV-2019 has not been found in humans before, 
no specific vaccine or treatment has been provided. 
Furthermore, drug therapy did not show optimum results 
in multiple organ failures [10], [11], [12], [13].
Renal involvement is prominent in this regard 
and it is recommended to check renal factors such as 
creatinine at admission [14], [15]. There is more need 
to conduct further studies in different conditions, for 
example, pregnant women, because the data of these 
conditions are sparse. Regarding that, many factors 
influence the development of any disease, special 
groups should be careful more [16], [17], [18], [19]. It is 
important to diagnose all suspected cases as soon as 
possible and to treat them quickly, to cut off the source of 
the infection. Conventional diagnostic testing methods, 
such as assessment to detect antiviral antibodies 
or viral antigens, have been clinically developed and 
used. New diagnostic solutions, including real-time 
polymerase chain reaction (RT-PCR) and microscopic-
based measurements, may be effective in monitoring 
epidemiological measures, along with preventive 
measures [20], [21].
Like other CoVs, COVID-19 nucleic acids can 
be detected in samples such as nasopharyngeal swabs, 
sputum, lower respiratory tract secretions, blood, and 
feces. Clinical signs and graphic findings provide an 
acceptable diagnosis. It is showed that fever (78.9%) 
and cough (67.7%) were the most common symptoms. 
Diarrhea (3.7%) and vomiting (5%) were rare. 
Abnormalities in computed tomography (CT) images 
of the chest were observed in 96% of patients infected 
with novel CoV, and in 82.1% of them, lymphopenia was 
recorded [22]. In Italy and Bulgaria, the same clinical 
characteristics of COVID-19 were reported [23], [24], 
[25]. Furthermore, the mortality of the COVID-19 varies 
country by country and sometimes city by city [26], [27].
Due to the high mortality of COVID and the 
WHO’s announcement of a pandemic on February 
2020, further studies are needed to identify disease 
symptoms, prognosis, graphical, and paraclinical 
findings for definitive diagnosis and subsequent 
treatment. In this study, the clinical and demographic 
characteristics of the dead patients following COVID-19 
development were evaluated.
Methods
In this descriptive-analytical cross-sectional 
study performed as a retrospective, the total numbers 
of patients died due to COVID-19 (n = 62) were 
studied in Modarres Hospital, Tehran. The existing 
records of patients who died following COVID-19 were 
examined through census sampling and the variables 
of age, gender, body mass index (BMI), comorbidity, 
symptoms, liver profile, lipid profile, hemoglobin, 
platelet, white blood cell (WBC), lymphocytes, 
neutrophils, C-reaction protein (CRP), RT-PCR 
(for partial diagnosis), creatine phosphokinase 
(CPK), creatinine, blood urea nitrogen, potassium, 
magnesium, and sodium were examined.
Inclusion criteria were the patients with 
approved COVID-19 died within April 2020. Exclusion 
criterion was the illegible file of the patients. Indeed, 
the method of sampling was census. Regarding the 
case definition, the approved COVID-19 case was 
considered as a patient with a positive respiratory 
sample performed by PCR method (nasopharyngeal 
swab RT-PCR) with a sensitivity and specificity of 
78.2% and 98.8%, respectively [28].
There were 430 hospitalized patients at 
Modarres Hospital in April 2020, and 62 of whom died 
this month. The diagnosis was based on radiological 
chest X-ray, CT scan, PCR test, and initial symptoms 
of COVID-19 (evidence of extensive pulmonary 
involvement with tachycardia and respiratory rate 
above 25 or higher, fever, myalgia, and cough). O2 
saturation was below 93%, requiring hospitalization at 
the intensive care unit at the beginning of the visit or 
short-term after admission. These patients underwent 
treatment protocols based on the respiratory pattern 
and clinical findings and pulmonary scintigraphy 
in the middle and severe groups of COVID-19, 
including hydroxychloroquine with or without 
Kaletra@ (Lopinavir+Ritonavir) and sometimes 
oseltamivir. Some patients were given antibiotics 
and corticosteroids, intravenous immunoglobulin, 
and Vitamin C ampoules. Depending on the patient’s 
respiratory progression or progression of the disease 
to acute respiratory distress syndrome (PiO2/FiO2 
<300) or acute lung injury (PiO2/FiO2 <200), or suffering 
from respiratory distress or severe decrease of O2 
saturation, they needed intubation and mechanical 
ventilation.
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Statistical analysis
Descriptive statistics (frequency, mean, and 
standard deviation) and analytical statistics were used 
to analyze the data analysis. All the analysis was 
conducted using SPSS. The Kolmogorov–Smirnov 
statistical test demonstrated that the data did not have 
a normal distribution. Thus, the nonparametric tests 
were used in order to analyze the data. p < 0.05 was 
considered statistically significant.
Ethical consideration
This research was performed according to the 
Declaration of Helsinki. Informed written consent was 
obtained from the patients, and the study was approved 
by the Ethics Committee of Shahid Beheshti University 
of Medical Sciences (ethical code: IR.SBMU.RETECH.
REC.1399.034, available at: http://ethics.research.
ac.ir/IR.SBMU.RETECH.REC.1399.034).
Results
In this study, 62 patients who died due 
to confirmed COVID-19 in Modarres Hospital in 
Tehran. Regarding gender, 71% of patients were 
male and 69.4% had positive PCR test results, 
indicating low sensitivity of the test. Regarding age 
as an effective factor, 90.3% of patients had above 
60 years old. Regarding lymphocytopenia, 56.5 
of patients had lymphocytopenia. Indeed we used 
absolute lymphocyte count formula for calculating 
lymphocytopenia [29]. Thrombocytopenia is divided 
into three groups: mild (100,000–150,000 platelets/
µL), moderate (50,000-100,000 platelets/µL), and sever 
(<50,000 platelets/µL) (Table 1). In terms of clinical and 
paraclinical characteristics, patients had a mean BMI 
of 28.34 kg/m2 (overweight class). The mean age was 
67.62 years, with symptoms lasting 6.24 days, length 
of hospital stay 6.64 days, and staying in the intensive 
care unit for 4.70 days. The mean serum creatinine and 
blood urea were 3.18 g/dl and 125.9 mg/dl, respectively, 
indicating renal involvement. Other laboratory variables 
are listed in Table 2. Regarding involvement of organs, 
33.9% of patients had solely pulmonary involvement, 
which was often associated with cardiac involvement 
and systemic infection (17.7%). However, all patients 
had pulmonary involvement accompanied by other 
organ involvements. In 16.16% of cases, pulmonary 
involvement was associated with renal involvement and 
Table 1: The number of patients by lymphocytopenia, PCR, 
BMI, age, gender, and platelet patients with COVID-19
Variable Number of patients Percent
Gender
Female 18 29.0
Male 44 71.0
PCR test
Positive 43 69.4
Negative 19 30.6
Lymphocytopenia
Yes 35 56.5
No 26 41.9
BMI (kg/m2)
18.5–24.9 7 22.6
25–29.9 15 48.4
30–39.9 9 29.0
Platelet (Count per mL)
100–150 24 40.0
50–100 8 13.3
<50 2 3.3
Age (year)
28–40 1 1.6
41–60 5 8.1
>60 56 90.3
BMI: Body mass index, PCR: Polymerase chain reaction.
Table 2: Clinical and paraclinical characteristics of patients 
with COVID-19
Variable Minimum Maximum Mean Standard 
deviation
Reference range
Age (year) 28.00 95.00 67.62 15.07 -
BMI (kg/m2) 21.40 39.50 28.34 4.13 -
Duration of sign 
(Day)
1.00 20.00 6.24 4.14 -
Duration of 
admission sign (Day)
1.00 20.00 6.48 4.64 -
Stay in the intensive 
care unit sign (Day)
1.00 17.00 4.70 4.39 -
Duration of 
intubation sign (Day)
1.00 17.00 4.34 4.25
WBC (Count per 
microliter)
2,700 177,000 15,470 22,330 4500–11,000
Lym (Count per 
microliter)
2,800 90,000 11,610 15,460 800–5000
Neut (Count per 
microliter)
5,900 96,000 82,260 18,070 5000–10,000
Plt (Count per 
microliter)
22,000 249,0000 208,230 312,130 150,000–450,000
Hb (mg/dl) 6.60 128.00 15.52 20.64 Male: 13.5–17.5
Female: 12–15.5
CRP (mg/L) 1.00 3.00 2.32 0.70 <10
AST (mg/dl) 27.00 4680.00 237.10 715.77 8–48
ALT (mg/dl) 21.00 2800.00 146.78 393.07 7–55
ALP (mg/dl) 91.00 453.00 217.21 91.25 40–129
Urea (mg/dl) 31.00 370.00 125.96 84.31 7–20
Creatinine (mg/dl) 0.96 14.80 3.18 2.94 0.84–1.21
LDH (U/L) 2.50 3408.00 1167.65 681.31 140–280
CPK (mcg/L) 33.00 1507.00 459.65 387.01 10–120
SpO2 (%) 50.00 92.50 78.62 8.59 95–100
BMI: Body mass index, WBC: White blood cell, CRP: C-reaction protein, CPK: Creatine phosphokinase. 
ALT: Aspartate aminotransferase.
Table  3:  The  number  of  organs  affected  following  novel 
coronavirus infection
Involved organ Number of patients Percent
Lung 21 33.9
Lung and kidney 10 16.1
Lung, systematic infection 5 8.1
Lung, kidney, and systematic infection 4 6.5
Lung, systematic infection and heart 11 17.7
Lung, kidney, and heart 5 8.1
Lung, kidney, heart, and systematic infection 4 6.5
Lung and heart 2 3.2
Total 62 100.0
11 patients undergone hemodialysis and 18 patients 
developed acute kidney injury. One person developed 
meningoencephalitis (Table 3). Regarding comorbidities, 
24.4% of patients had hypertension and heart disease. 
Some affected patients had diabetes, gastrointestinal 
diseases, and cancer (Table 4). Regarding symptoms, 
19% of patients had fever, cough, and shortness of 
breath together. However, 72% of patients showed 
fever. Some affected patients had diarrhea, lethargy, 
and fatigue (Table 5). A comparison of comorbidities 
by gender showed no significant differences (Table 6). 
In patients more than 60 years, the frequency of organ 
failures was significantly different and 10 patients were 
involved with renal failure, 13 patients with heart disease, 
and six patients with systematic infection. Approximately 
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all patients were involved with pulmonary disease 
(Table 7). Table 8 presents some predictive factors 
increasing the chance of mortality following COVID-
19 including shortness of breath (odds ratio: 1.821, 
p: 0.011), age more than 60 years (odds ratio: 4.022, 
the mean age was 67.62 years; with symptoms lasting 
6.24 days. The mean serum creatinine and blood 
urea were 3.18 g/dl and 125.9 mg/dl, respectively, 
indicating renal involvement. All patients had 
pulmonary involvement accompanied by other organ 
involvements. Regarding symptoms, 19% of patients 
had fever, cough, and shortness of breath together. 
However, 72% of patients showed fever. Some 
affected patients had diarrhea, lethargy, and fatigue. 
A comparison of comorbidities by gender showed no 
significant differences. Regarding age, the frequency 
of patients died following COVID-19 <60 was low and it 
Table 8: Logistic regression to predict the binary outcome 
(death following COVID-19)
Variable B SE p-value Odds ratio 95% CI
Lower Upper
Shortness of breath 0.599 0.140 0.011 1.821 1.112 1.928
HB −0.994 1.011 0.098 0.370 0.211 2.344
LDH −1.084 1.141 0.599 0.338 0.138 12.112
Neut 0.0009 0.411 0.813 1.001 0.872 4.371
Lymph 0.207 1.057 0.342 1.230 0.239 15.091
Cough 1.099 0.982 0.067 3.003 0.919 43.310
Age more than 60 years 1.391 0.156 0.001 4.022 2.471 4.560
Hypertension 0.664 0.131 0.036 1.944 1.331 2.229
Diabetes 0.734 0.027 0.002 2.085 1.989 2.215
Cancer 1.361 0.141 0.012 3.902 2.656 4.625
Table 7: The number of organ failures in patients with COVID-19
Organ Age more 
than 60 years
Age less than 
60 years
p-value χ2
Lung 17 4 0.018 16.956
Lung and kidney 10 0
Lung + systematic infection 4 5
Lung and kidney + systematic 
infection
4 0
Lung + systematic infection + heart 9 2
Lung and kidney +heart 4 1
Lung and heart 0 2
Table 4: The number of comorbidities in patients with 
COVID-19
Comorbidity Number of patients Percent
Hypertension 5 11.1
Heart 4 8.9
Diabetes 3 6.7
Gastrointestinal 2 4.4
Cancer 6 13.3
Heart and diabetes 6 13.3
Heart and gastrointestinal 2 4.4
Hypertension and heart 11 24.4
Hypertension and diabetes 3 6.7
Hypertension and cancer 1 2.2
History of surgery 1 2.2
Cerebrovascular accident 1 2.2
Table 5: The number of symptoms in patients with COVID-19
Symptoms Number of patients Percent
Fever 1 1.6
Cough 2 3.3
Shortness of breath 8 13.1
Diarrhea 1 1.6
Fatigue 3 4.9
Lethargy 1 1.6
Fever and shortness of breath 10 16.4
Fever, cough, and shortness of breath 19 31.1
Fever and lethargy 1 1.6
Diarrhea, cough, and shortness of breath 2 3.3
Fever, cough, and lethargy 3 4.9
Fever, shortness of breath, and fatigue 10 16.4
Table 6: Comparison of comorbidities by gender
Comorbidity Gender (%) Statistics
Female Male
Hypertension 1 (7.1) 4 (12.9) X2 Fisher = 10.769 p = 0.444
Heart 2 (14.3) 2 (6.5)
Diabetes 1 (7.1) 2 (6.5)
Gastrointestinal 0 (0) 2 (6.5)
Cancer 0 (0) 6(19.4)
Heart and diabetes 2 (14.3) 4(12.9)
Heart and gastrointestinal 0 (0) 2 (6.5)
Hypertension and heart 6(42.9) 5 (16.1)
Hypertension and diabetes 2 (14.3) 1 (3.2)
Hypertension and cancer 0 (0) 1 (3.2)
History of surgery 0 (0) 1 (3.2)
Cerebrovascular accident 0 (0) 1 (3.2)
p: 0.001), hypertension (odds ratio: 1.944, p: 0.036), 
diabetes (odds ratio: 2.085, p: 0.002), and cancer (odds 
ratio: 3.902, p: 0.012). The results of multiple regression 
showed that age can be one of the main predictive 
factors. It should be noted that other factors were not 
significant in univariate regression.
Discussion
Due to the emergence of COVID and the 
WHO’s announcement of a pandemic in and finally, 
the need for identifying the clinical and demographic 
characteristics of COVID-19, we conducted this study. 
In summary, our study showed that among 62 dead 
people due to COVID-19, 71% of patients were male 
and 69.4% had positive PCR test results, indicating 
low sensitivity of the test; 90.3% of patients had above 
60 years old; 56.5 of patients had lymphocytopenia; 
makes bias in interpretation. We should know that the 
majority of our study population consisted of patients 
who were above 60 years and this finding should not 
ignore the risk of mortality in younger patients. It is 
declared that some groups of people are more prone 
to develop COVID-19, including pregnant women and 
elderlies, in which older people are predisposed to 
this disease (age >55 years) [30]. The median age of 
patients with COVID-19 in a study by Richardson et al. 
was 63 years and 39.7% were female, while these 
results were consistent with our results [31].
Huang et al. found that 98% of patients with 
COVID-19 had a fever. They reported that patients 
referred with cough (76%), fatigue and muscle pain 
(44%), dyspnea (55%), sputum expectoration (28%), 
headache (8%), hemoptysis (5%), and diarrhea (3%). 
Laboratory tests showed that 25% of infected patients 
had leukopenia and 64% had lymphocytopenia. 
Aspartate aminotransferase levels are elevated in 
37% of patients. Myocarditis was diagnosed in 12% 
of patients, and very sensitive troponin I levels were 
significantly increased in these patients. Abnormalities 
in chest CT images were observed in 100% of 
patients [32]. According to Table 7, our study declared 
that COVID-19 is a multi-organ disease; in such a way 
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that single-organ failure (lung) was shown in just 21 
patients. In 10 patients, lung and kidney were involved 
together. Renal involvement was detected in 18 
patients, accompanied by lung and heart involvement.
In a study entitled “Presenting characteristics, 
comorbidities, and outcomes among 5700 patients 
hospitalized with COVID-19 in the New York City area” 
done by Richardson et al., the results indicated 3.2% 
of patients were treated by renal dialysis. Richardson 
et al. reported hypertension as the most common 
comorbidity consistent with our study because heart 
disease, especially hypertension, was observed a lot 
in patients [31].
Zhao et al. revealed that Asian men were more 
likely to develop CoV infection in 2019 [5]. Guan et al. 
reported 1099 cases of the new CoV-2019 infection. They 
found that fever (78.9%) and cough (67.7%) were the most 
common symptoms. Diarrhea (3.7%) and vomiting (5%) 
were rare. Abnormalities in CT images of the chest were 
observed in 96% of patients infected with COVID-19, and 
in 82.1% of them, lymphopenia was recorded [22]. These 
results were consistent with our results. Approximately 
the reported symptoms and organ failure were recorded 
for the dead cases. There were no notable differences 
between the reviewed studies and the results of our study. 
The display of COVID-19 in Asian people is the same. 
While in a study by Richardson et al., 30.7% was febrile, 
that’s why the display of symptoms can be changed by 
geographical differences [31]. Our study found more fertile 
patients compared to the Richarson et al. study.
Conclusion
According to our results, the majority of died 
people affected by COVID-19 were overweight and 
more than 60 years old. In people who were more than 
60 years, multi-organ failure was notable. Fever, cough, 
and shortness of breath were dominant symptoms like 
other studies but neurological complications following 
COVID-19 as meningoencephalitis is possible that can 
be used as a differential diagnosis. COVID-19 in people 
more than 60 years rings a dreadful bell to medical staff. 
Lung is always involved in both genders. We did not 
found differences between male and female regarding 
comorbidity, symptoms, and mortality rate.
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